Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation reports news on its MRI-compatible medical-device business, including non-magnetic IV infusion pump systems, patient vital signs monitoring systems, accessories, disposables and related services sold to hospitals and acute care facilities. Company updates often describe financial results, revenue and earnings guidance, cash generation, and regular or special cash dividends.
IRMD news also covers product activity for systems such as the 3880 MRI-compatible patient vital signs monitor and the next-generation 3870 MRI-compatible IV infusion pump, along with investor conference participation and recognition tied to growth and financial performance.
iRadimed Corporation (NASDAQ: IRMD) reported Q3 2020 revenue of $7.7 million, down from $10.0 million in Q3 2019. Net income fell to $1.1 million or $0.09 per diluted share, compared to $2.5 million or $0.20 for Q3 2019. For the first nine months, revenue declined to $23.2 million from $27.6 million in 2019, with net income of $0.7 million or $0.06 per diluted share. The company held $49.9 million in cash and investments as of September 30, 2020. Financial guidance remains unavailable due to uncertainties from the COVID-19 pandemic.
IRADIMED CORPORATION (NASDAQ: IRMD) will disclose its 2020 third-quarter financial results on October 30, before market opening. Management will host a conference call at 11:00 a.m. ET to discuss the results and address queries. Interested parties can join the call by dialing designated numbers or listen online. IRADIMED specializes in MRI-compatible medical devices, being the sole provider of a non-magnetic IV infusion pump system, which ensures safety during MRI procedures, particularly for critically ill patients and children.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its second quarter financial results for 2020 on July 30, 2020, before market open. Management will host a conference call at 11:00 a.m. ET that day to discuss the results and answer questions. Interested parties can join the call by dialing 1-844-413-1781 (domestic) or 1-716-247-5767 (international) with reservation code 8281889. The call will be accessible online and a recording will be available on their website for 90 days thereafter.
Summary not available.